Submitter |
RCV |
SCV |
Clinical significance |
Condition |
Last evaluated |
Review status |
Method |
Comment |
Knight Cancer Institute, Oregon Health and Science University |
RCV000721114 |
SCV000845775 |
likely pathogenic |
Chronic myelomonocytic leukemia |
2018-09-25 |
no assertion criteria provided |
clinical testing |
Primary patient samples are sensitive to kinase inhibitors (quizartinib and sorafenib) |
The information on this website is not intended for direct
diagnostic use or medical decision-making without review by a
genetics professional. Individuals should not change their
health behavior solely on the basis of information contained on
this website. Neither the University of Utah nor the National
Institutes of Health independently verfies the submitted
information. If you have questions about the information
contained on this website, please see a health care
professional.